Longevity: From Buzzword To Nascent Business Category
In January 2021, Nature, one of the most popular journals in the life sciences field, began publishing a journal dedicated to aging called Nature Aging. In addition, a report by Longevitytech.fund, found that the amount of investment in this field has grown steadily over the past decade. A number of high-profile figures are backing the space. Jeff Bezos reportedly has invested in Altos Labs, which is focused on cellular reprogramming. Alphabet's Calico Life Sciences is another key player, exploring how biology and machine learning can combine to extend human life. And in one of the largest known personal investments in the space, OpenAI CEO Sam Altman reportedly committed $180 million of his own money into Retro Biosciences, a startup aiming to extend human lifespan by ten years. These bold moves suggest that longevity is no longer a fringe idea—it's becoming a serious venture category.
But for all the headlines and hype, longevity remains an emerging and somewhat amorphous sector. Are we trying to live longer, or live better? Some initiatives aim to extend the human lifespan, pushing the boundaries of biological possibility; whereas others are focused on the improving the health span—reducing and even aiming to prevent the number of years people spend in poor health. In addition, the science is still unsettled. Many of the businesses receiving significant capital are building on promising—but still emerging—research. This creates a uniquely complex environment for investors, entrepreneurs, and researchers alike. Navigating the longevity space requires not only technical and scientific literacy but also a healthy dose of skepticism. As the field gains traction, the challenge lies in separating breakthroughs from buzzwords, and robust evidence from mere enthusiasm.
In the midst of this uncertainty, one initiative is trying to bring order to the chaos. Longevity Global, a nonprofit founded by neuroscientist and entrepreneur Dr. Christin Glorioso, is building a global community to connect researchers, entrepreneurs, and investors in the longevity ecosystem. Communities like Longevity Global play a vital role in shaping nascent fields. Academic research has long shown that communities are critical in the early stages of market formation. They help legitimize the space, encourage knowledge sharing, and accelerate innovation.
Glorioso, who is also CEO of NeuroAge Therapeutics, which uses AI to track and prevent brain aging, started the organization out of a personal need. 'When I launched my company in 2022, I was looking for a community of like-minded people interested in the longevity space, but couldn't find many,' she explains. That absence inspired action. Today, Longevity Global has grown to over 926 members, with a unique mix of stakeholders: 44% are entrepreneurs, 38% are researchers, and 15% are investors. The organization is designed to foster peer-to-peer learning, focusing not only on scientific developments but also on the business of longevity—how to fund, scale, and build credible ventures in a field still defining its boundaries. It acts as a connective tissue for the ecosystem, helping stakeholders find collaborators, learn from one another, and collectively solve the complex problems associated with aging.
The community is expanding globally, with chapters in San Francisco, New York City, Dubai, Switzerland, and, most recently, Boston. "Boston has the elements of a great longevity ecosystem—cutting-edge research and a thriving startup scene," says Justin Taylor, Head of the Boston Chapter. "We're building a collaborative community to help advance it further." Recognizing the accelerating role of AI in longevity research, the Boston chapter—together with partners Mindvyne and 3cubed.ai—will host the Aging Code Summit in June. The event will explore the future of aging through the lens of AI and feature a pitchfest showcasing longevity startups, offering a front-row seat to some of the most promising ideas in the field.
As longevity continues to evolve from concept to category, it will require more than just capital—it will need coordination, credibility, and collaboration. Communities that bring together stakeholders across science, startups, and finance may influence how this field matures. In the years ahead, the success of the longevity sector may depend less on isolated breakthroughs and more on the ecosystem's ability to learn, adapt, and grow together.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Breakthrough study finds deficiency of this common nutrient could contribute to Alzheimer's
A deficiency of the metal lithium in the body could be a key factor contributing to the development of dementia in Alzherimer's patients, a groundbreaking new study reveals. The decade-long research, published in the journal Nature, shows for the first time that lithium occurs naturally in the brain and maintains the normal function of all its major cell types, preventing nerves from degradation. Scientists from Harvard Medical School found that lithium loss in the human brain is one of the earliest changes leading to Alzheimer's, while in mice, a similar lithium depletion accelerated memory decline. A reduced lithium level was found in some cases due to the metal's impaired uptake and its binding to amyloid plaques, which are known to be smoking gun signs of Alzheimer's. Researchers also showed that a new type of lithium compound – lithium orotate – can avoid capture by amyloid plaques and restore memory in mice. In the study, scientists used an advanced type of mass spectroscopy chemical analysis method to measure trace levels of about 30 different metals in the brain and blood samples from a range of people, including cognitively healthy people, those in an early stage of dementia, and those with advanced Alzheimer's. The analysis revealed that lithium was the only metal with markedly different levels across groups, which also seemed to change at the earliest stages of memory loss. 'Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C,' study senior author Bruce Yankner said. 'It's the first time anyone's shown that lithium exists at a natural level that's biologically meaningful without giving it as a drug,' Dr Yankner said. Although lithium compounds have been historically in use to treat a range of mental conditions like bipolar disorder and major depressive disorder, in these cases, they are given at much higher concentrations that could even be toxic to older people. Scientists have now found that lithium orotate is effective at one-thousandth this dose – enough to mimic the natural level of lithium in the brain. The latest findings with lithium orotate, however, needs to be confirmed in humans via clinical trials. Yet, researchers suspect that measuring lithium levels could help screen people for early Alzheimer's. The findings revise the theory of Alzheimer's disease, which affects nearly 400 million people worldwide, offering a new strategy for early diagnosis, prevention, and treatment. Decades of studies have shown that Alzheimer's disease involves an array of brain abnormalities, including clumps of the protein amyloid beta, tangles of the protein tau, and a loss of the brain's protective protein REST. However, these abnormalities have never fully explained the condition. For instance, it remains unclear why some people with Alzheimer's-like changes in the brain never go on to develop dementia or cognitive decline. Recent treatments developed to target amyloid beta plaques also don't seem to reverse memory loss, only modestly reducing the rate of cognitive decline. Now, scientists say lithium could be the critical missing link. 'The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach,' Dr Yankner said. 'You have to be careful about extrapolating from mouse models, and you never know until you try it in a controlled human clinical trial... But so far the results are very encouraging,' he added. Solve the daily Crossword
USA Today
6 hours ago
- USA Today
Jillian Michaels breaks silence on 'Biggest Loser' Netflix doc, co-star Bob Harper
Jillian Michaels is slamming Netflix's docuseries about "The Biggest Loser" and is showing the receipts to back it up. The celebrity fitness trainer took to Instagram on Aug. 19 in a series of posts to slam claims from "Fit for TV: The Reality of the Biggest Loser" (now streaming), which gave former fans a second course of the small moments and big missteps from NBC's 18-season competition series that aired from 2004-16. Though many lost weight throughout the series, the tactics at times posed a risk to participants and their esteem. Tracey Yukich suffered a near-death experience during a challenge to kick off Season 8. Michaels supplied some contestants with caffeine pills, though caffeine was banned by the show's physician, Robert Huizenga. And competitors were asked to participate in sometimes humiliating temptation challenges, when they were enticed with high-calorie treats or building towers made of bread using their mouths. In a series of lengthy statements, Michaels took aim at a range of allegations about her, including one that she said "you're going to make me a millionaire" to a contestant (a claim she said is false), plied contestants with caffeine pills and encouraged calorie restriction. A post shared by Jillian Michaels (@jillianmichaels) "With respect to the allegation that I restricted contestants from eating enough calories: I have an example of a direct written correspondence with a contestant, while she was home for the holidays during filming, in which I explicitly instructed her to consume 1,600 calories per day," Michaels said in one Instagram caption. She continued: "Additionally, the two other emails posted here are standard communications with the show's producers and medical staff, emphasizing the ongoing priority of ensuring contestants were adequately nourished and the need to provide a steady supply of fresh food in the BL house to guarantee ready access to calories." Michaels – who said that "caffeine was NEVER banned" on the show – added that the show's medical advisor, Dr. Robert Huzienga, "did approve caffeine pills on many seasons of 'Biggest Loser.'" Bob Harper accuses Jillian Michaels of not reaching out after his 2017 heart attack The trainer turned conservative commentator added that "Bob Harper not only knew about the caffeine pills the 'stackers fat burner' were actually his suggestion. I wanted to use my brand instead because they were cleaner and had no more than 200mg of caffeine." Both Harper and Huzienga appeared in the documentary, while Michaels did not. On social media, Michaels also spoke about rampant speculation surrounding her relationship with former costar Harper. In a screenshot shared in one carousel, Michaels said that "the last image is my second to last text ever to Bob Harper. Take from it what you will." The message from Michaels to Harper allegedly said, "I really think it's (bad) of you to not even respond to my texts. It's this kind of thing that always makes me so disappointed (in) our relationship." Her comments raise new questions about her relationship with Harper after years of rift rumors. In February 2017, Harper suffered a heart attack during a workout in New York City. He told TMZ at the time that after he collapsed at the gym, a doctor who was there performed CPR on him. In a recent interview in The Guardian, Harper claimed that while many of his "Biggest Loser" colleagues reached out after his medical ordeal, Michaels notably did not. "We weren't besties, but we were partners on a television show for a very long time," Harper told the outlet, adding that the silence "spoke volumes to me." Contributing: Edward Segarra, Erin Jensen, USA TODAY
Yahoo
8 hours ago
- Yahoo
Is Wall Street Bullish or Bearish on Thermo Fisher Scientific Stock?
With a market cap of $155.6 billion, Thermo Fisher Scientific Inc. (TMO) stands as a global leader in serving science, providing cutting-edge technologies, services, and solutions that drive research and enhance healthcare. The Waltham, Massachusetts-based company operates through four core segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services. Shares of TMO have underperformed the broader market, dropping 19% over the past year and 6% in 2025. In comparison, the broader S&P 500 Index ($SPX) has gained 16.4% over the past 52 weeks and 9.7% on a YTD basis. More News from Barchart Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Powell, Trump Talks and Other Can't Miss Items this Week 'My Kid Will Never Ever Be Smarter Than an AI': OpenAI's Sam Altman Warns Most Kids Won't Know a World Without AI Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Looking closer, the stock has also trailed behind the Health Care Select Sector SPDR Fund's (XLV) 10.8% decline over the past 52 weeks and a marginal fall year-to-date. Thermo Fisher released its Q2 2025 earnings on July 23, and its shares popped 9.1%. It reported revenue of $10.85 billion, a 3% year-over-year increase (with 2% organic growth). Adjusted EPS was $5.36, compared to $5.37 in the prior year, while adjusted operating income rose to $2.38 billion from $2.35 billion in the year-ago quarter. Thermo Fisher also highlighted the launch of next-generation instruments, including Orbitrap Astral Zoom, Orbitrap Excedion Pro, and the Krios 5 Cryo-TEM, as well as an expanded DynaDrive single-use bioreactor portfolio. For the fiscal year ending in December 2025, analysts expect TMO's adjusted EPS to grow 3% year-over-year to $22.52. The company's earnings surprise history is promising. It topped the consensus estimates in the last four quarters. Among the 26 analysts covering the stock, the consensus rating is a 'Strong Buy.' That's based on 18 'Strong Buy' ratings, three 'Moderate Buys,' and five 'Holds.' This configuration has been stable over the past months. On July 28, UBS analyst Dan Leonard downgraded Thermo Fisher to 'Neutral' from 'Buy,' cutting the price target to $460 from $500, citing concerns that persistent headwinds could weigh on life sciences R&D, which accounts for about half of the company's sales. UBS also forecast 2026 organic sales growth of 4%, 200 basis points below consensus, and reduced its longer-term outlook. TMO's mean price target of $553.60 implies a modest potential upside of 13.2% from the current price levels. Similarly, the Street-high price target of $650 indicates that the stock could soar by 32.9%. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
